
Commentary by Adi Diab MD, PGY-3
This past week on January 21th, Medical Grand Rounds was given by guest speaker Dr. John Griffin who shared his knowledge of the role of Activate Protein …

Commentary by Adi Diab MD, PGY-3
This past week on January 21th, Medical Grand Rounds was given by guest speaker Dr. John Griffin who shared his knowledge of the role of Activate Protein …
Commentary by Rachana Jani MD, PGY-2
As recently reported in ShortCuts, Byetta recently made headlines after the suggestion of a mortality benefit for patients taking the drug in a small subset of the Accord study. So is this the new golden drug …
Commentary by Marilena S. Antonopoulos Pharm.D, Pharmacology Section Editor
Until recently, drugs safety alerts (aka “Dear Doctor lettersâ€) were sent out to physicians through traditional U.S. mail, a slow and error-prone process. These alerts …
Commentary by Marilena S. Antonopoulos, PharmD, Pharmacology Editor
On July 8th, the FDA notified the manufacturers of fluoroquinolone antimicrobial drugs that a Boxed Warning in the product labeling and a Medication Guide …
Commentary by Melissa Freeman, PGY-2Â
As summertime is just around the corner, many begin to evaluate whether their bodies are ready to expose what has been hidden under those bulky winter clothes. Between …
Commentary by David Hatcher, MSIII (reviewed by Neil Shapiro, MD Editor-In-Chief, Clinical Correlations)
C.M. is a 68 year-old retired Caucasian male with a past medical history significant for coronary artery disease, …
Future Medicine is a new section of Clinical Correlations devoted to hot areas of research and development in various fields of medicine. In tihis series, we will highlight treatments in their infancy, from basic research …
Class act is a feature of Clinical Correlations written by NYU 3rd and 4th year medical students. These posts focus on evidenced based answers to clinical questions related to patients seen by our …